Johnson & Johnson (NYSE:JNJ) EVP Vanessa Broadhurst Sells 6,197 Shares

Johnson & Johnson (NYSE:JNJ) EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Johnson & Johnson Stock Up 0.6%

Shares of NYSE JNJ opened at $244.89 on Thursday. The stock has a market cap of $590.17 billion, a PE ratio of 22.16, a P/E/G ratio of 2.36 and a beta of 0.35. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $246.35. The company has a 50-day moving average of $219.71 and a 200 day moving average of $198.21.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The business had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.1%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Institutional Investors Weigh In On Johnson & Johnson

Institutional investors and hedge funds have recently modified their holdings of the company. Brighton Jones LLC boosted its stake in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the period. United Bank increased its stake in Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after buying an additional 4,876 shares during the period. Sivia Capital Partners LLC lifted its holdings in Johnson & Johnson by 13.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after buying an additional 692 shares in the last quarter. Wealth Group Ltd. boosted its position in Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock valued at $226,000 after buying an additional 168 shares during the period. Finally, Sendero Wealth Management LLC grew its stake in shares of Johnson & Johnson by 4.2% in the second quarter. Sendero Wealth Management LLC now owns 8,353 shares of the company’s stock worth $1,276,000 after acquiring an additional 337 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Announced a >$1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Pennsylvania as part of a multi‑year U.S. manufacturing expansion, signaling long‑term capacity growth for its biologics/cell therapy pipeline. Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
• Positive Sentiment: FDA approved a simplified monthly dosing schedule for RYBREVANT FASPRO (amivantamab + hyaluronidase), improving convenience for EGFR+ NSCLC patients and potentially boosting uptake and product competitiveness. FDA approves RYBREVANT FASPRO as the only EGFR-targeted therapy that can be administered once a month
• Positive Sentiment: Received FDA Breakthrough Therapy Designation for subcutaneous amivantamab (RYBREVANT FASPRO) in advanced head & neck cancer — a regulatory accelerator that can shorten development timelines and enhance commercial prospects if confirmatory data follow. RYBREVANT FASPRO receives U.S. FDA Breakthrough Therapy Designation for head and neck cancer
• Positive Sentiment: Reinforced shareholder returns with a quarterly dividend increase (quarterly payout raised to $1.30), supporting JNJ’s income appeal and dividend‑investor base. Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?
• Neutral Sentiment: Options activity has picked up interest around JNJ, which can amplify near‑term moves but doesn’t by itself change fundamentals. Watch for large/ directionally concentrated trades. Behind the Scenes of Johnson & Johnson’s Latest Options Trends
• Neutral Sentiment: Street attention and analyst writeups (Zacks, TipRanks) are keeping JNJ in the spotlight; useful for sentiment tracking but incremental to fundamental drivers. Johnson & Johnson (JNJ) Is a Trending Stock
• Neutral Sentiment: A small contract extension with Trellus Health keeps an adherence/support program in place; operationally positive but immaterial to JNJ’s top line. Trellus Health shares double on J&J extension
• Negative Sentiment: Ongoing talc litigation and recent verdict coverage continue to highlight legal risk and valuation uncertainty, which can cap multiple expansion despite operational positives. Johnson And Johnson Talc Verdict Puts Legal Risks And Valuation In Focus

Analyst Ratings Changes

JNJ has been the subject of a number of analyst reports. Bank of America upped their price objective on shares of Johnson & Johnson from $220.00 to $221.00 and gave the company a “neutral” rating in a report on Thursday, January 22nd. Leerink Partners increased their price target on shares of Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research note on Thursday, January 22nd. Scotiabank reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Wells Fargo & Company upped their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Finally, Royal Bank Of Canada upped their price target on Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $233.73.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.